RBC Capital Reiterates Sector Perform on Biomarin Pharmaceutical, Maintains $100 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has reiterated a 'Sector Perform' rating on Biomarin Pharmaceutical (NASDAQ:BMRN) and maintained a $100 price target.
November 07, 2023 | 6:09 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
RBC Capital has reiterated a 'Sector Perform' rating on Biomarin Pharmaceutical and maintained a $100 price target.
The reiteration of the 'Sector Perform' rating and the maintenance of the $100 price target by RBC Capital indicates that the analyst believes the stock is fairly valued at its current price. This is likely to have a neutral impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100